June 18, 2024Neuro-OncologyOpen Access

MDB-101. Targeting Ctps1 and Nucleotide Biosynthesis Pathways as a Novel Therapeutic Approach in Myc-Amplified Medulloblastoma

View Full Paper

Ask AI

Bookmark

Dual inhibition of CTPS1 and CHK1 significantly suppresses cell viability and slows tumor progression in aggressive MYC-amplified medulloblastoma models.
Fewer than 50% of patients survive five years with Group 3 medulloblastoma, but targeted CTPS1 inhibition effectively disrupts tumor sphere proliferation.
Highlights a rational combination targeting de novo pyrimidine synthesis and ATR/CHK1 pathway signaling; orthotopic mouse model requires further translation.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical study reveals that dual inhibition of CTPS1 and CHK1 suppresses tumor growth in MYC-amplified medulloblastoma models, highlighting a pyrimidine synthesis vulnerability.

Cite This Study

Hathaway et al. (2024) studied this question.

synapsesocial.com/papers/68e6452bb6db6435875d667b https://doi.org/10.1093/neuonc/noae064.549

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study reveals that dual inhibition of CTPS1 and CHK1 suppresses tumor growth in MYC-amplified medulloblastoma models, highlighting a pyrimidine synthesis vulnerability.

MDB-101. Targeting Ctps1 and Nucleotide Biosynthesis Pathways as a Novel Therapeutic Approach in Myc-Amplified Medulloblastoma

Key Points

Discussion

Implication

Cite This Study

MDB-101. Targeting Ctps1 and Nucleotide Biosynthesis Pathways as a Novel Therapeutic Approach in Myc-Amplified Medulloblastoma

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading